Technique and short-term outcomes of surgical treatment in patients with renal cell carcinoma and tumor venous thrombosis: experience of the Urology Clinic, N.N. Blokhin National Medical Research Center of Oncology

IF 0.1 Q4 ONCOLOGY
V. Matveev, M. Volkova, N. Vashakmadze, I. Stilidi
{"title":"Technique and short-term outcomes of surgical treatment in patients with renal cell carcinoma and tumor venous thrombosis: experience of the Urology Clinic, N.N. Blokhin National Medical Research Center of Oncology","authors":"V. Matveev, M. Volkova, N. Vashakmadze, I. Stilidi","doi":"10.17650/1726-9776-2021-17-2-17-32","DOIUrl":null,"url":null,"abstract":"Objective: to describe the technique of nephrectomy and thrombectomy used in patients with renal cell carcinoma (RCC) and tumor venous thrombosis of various levels, and to identify risk factors of in-hospital death among operated patients.Materials and methods. This study included 768 patients with RCC and tumor venous thrombosis who have undergone surgical treatment. Median age was 58 years (range: 16-82 years); the male to female ratio was 2.3:1. The symptoms of venous tumor thrombosis were identified in 199 patients (25.9 %). In the majority of patients (n = 509; 66.3 %), the tumor thrombus originated from the right renal vein. The cranial border of the tumor thrombus was located in the perirenal inferior vena cava (IVC) in 219 patients (28.5 %), subhepatic IVC in 201 patients (26.2 %), intrahepatic IVC in 171 patients (22.3 %), and above the diaphragm in 177 patients (23.0 %). We used an individual approach to choose an optimal method of vascular control and to identify indications for circulatory support. Two-thirds of patients (n = 512; 66.7 %) underwent temporary block of the second renal vein; 268 patients (34.9 %) - temporary block of the hepatoduodenal ligament and right heart; 11 patients (3.2 %) were operated on with cardiopulmonary bypass.Results. The median surgery time was 190 ± 63.6 min; median blood loss was 3,000 ± 71.6 mL (≥50 % of circulating blood in 35.1 % of patients). Intraoperative complications were registered in 23 patients (3.0 %); eight patients (1.0 %) died during surgery with 4 of them died due to pulmonary embolism (0.5 %), 3 died due to hemorrhagic shock (0.4 %), and 1 died due to myocardial infarction (0.1 %). One hundred and ninety individuals (25.0 %) developed postoperative complications with Clavien-Dindo grade III-V complications observed in 115 cases (15.1 %). Forty-one patients (5.3 %) died in the early postoperative period. The causes of death included multiple organ dysfunction (n = 21; 2.8 %), pulmonary embolism (n = 7; 0.9 %), sepsis (n = 6; 0.8 %), stroke (n = 4; 0.5 %), myocardial infarction (n = 2; 0.2 %), and RCC progression (n = 1; 0.1 %). We have identified several independent risk factors for in-hospital mortality, including ascites (hazard ratio (HR) 8.3; 95 % confidence interval (CI) 3.2-21.4; p < 0.0001), preoperative pulmonary embolism (HR 3.5; 95 % CI 1.3-9.4; p = 0.013), supradiaphragmatic thrombi (HR 1.5; 95 % CI 1.1-2.0; p = 0.003). The in-hospital mortality rate was 3.5 % (20/575) among patients with no risk factors, 9.8 % (16/163) among those with 1 risk factor, 40.0 % (10/25) among those with 2 risk factors, and 60.0 % (3/5) among those with 3 risk factors (area under the curve (AUC) 0.705; p <0.0001 for all).Conclusion. The incidence of severe complications and postoperative mortality rate in RCC patients with tumor venous thrombosis who have undergone nephrectomy and thrombectomy were 15.1 and 6.4 %, respectively. Risk factors for perioperative mortality included ascites, preoperative pulmonary embolism, and supradiaphragmatic thrombosis.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkourologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1726-9776-2021-17-2-17-32","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Objective: to describe the technique of nephrectomy and thrombectomy used in patients with renal cell carcinoma (RCC) and tumor venous thrombosis of various levels, and to identify risk factors of in-hospital death among operated patients.Materials and methods. This study included 768 patients with RCC and tumor venous thrombosis who have undergone surgical treatment. Median age was 58 years (range: 16-82 years); the male to female ratio was 2.3:1. The symptoms of venous tumor thrombosis were identified in 199 patients (25.9 %). In the majority of patients (n = 509; 66.3 %), the tumor thrombus originated from the right renal vein. The cranial border of the tumor thrombus was located in the perirenal inferior vena cava (IVC) in 219 patients (28.5 %), subhepatic IVC in 201 patients (26.2 %), intrahepatic IVC in 171 patients (22.3 %), and above the diaphragm in 177 patients (23.0 %). We used an individual approach to choose an optimal method of vascular control and to identify indications for circulatory support. Two-thirds of patients (n = 512; 66.7 %) underwent temporary block of the second renal vein; 268 patients (34.9 %) - temporary block of the hepatoduodenal ligament and right heart; 11 patients (3.2 %) were operated on with cardiopulmonary bypass.Results. The median surgery time was 190 ± 63.6 min; median blood loss was 3,000 ± 71.6 mL (≥50 % of circulating blood in 35.1 % of patients). Intraoperative complications were registered in 23 patients (3.0 %); eight patients (1.0 %) died during surgery with 4 of them died due to pulmonary embolism (0.5 %), 3 died due to hemorrhagic shock (0.4 %), and 1 died due to myocardial infarction (0.1 %). One hundred and ninety individuals (25.0 %) developed postoperative complications with Clavien-Dindo grade III-V complications observed in 115 cases (15.1 %). Forty-one patients (5.3 %) died in the early postoperative period. The causes of death included multiple organ dysfunction (n = 21; 2.8 %), pulmonary embolism (n = 7; 0.9 %), sepsis (n = 6; 0.8 %), stroke (n = 4; 0.5 %), myocardial infarction (n = 2; 0.2 %), and RCC progression (n = 1; 0.1 %). We have identified several independent risk factors for in-hospital mortality, including ascites (hazard ratio (HR) 8.3; 95 % confidence interval (CI) 3.2-21.4; p < 0.0001), preoperative pulmonary embolism (HR 3.5; 95 % CI 1.3-9.4; p = 0.013), supradiaphragmatic thrombi (HR 1.5; 95 % CI 1.1-2.0; p = 0.003). The in-hospital mortality rate was 3.5 % (20/575) among patients with no risk factors, 9.8 % (16/163) among those with 1 risk factor, 40.0 % (10/25) among those with 2 risk factors, and 60.0 % (3/5) among those with 3 risk factors (area under the curve (AUC) 0.705; p <0.0001 for all).Conclusion. The incidence of severe complications and postoperative mortality rate in RCC patients with tumor venous thrombosis who have undergone nephrectomy and thrombectomy were 15.1 and 6.4 %, respectively. Risk factors for perioperative mortality included ascites, preoperative pulmonary embolism, and supradiaphragmatic thrombosis.
肾细胞癌合并肿瘤静脉血栓形成的手术治疗技术及近期疗效:N.N. Blokhin国家肿瘤医学研究中心泌尿外科诊所的经验
目的:介绍肾细胞癌(RCC)及不同程度肿瘤静脉血栓形成患者行肾切除术及取栓术的方法,探讨手术患者院内死亡的危险因素。材料和方法。本研究纳入768例接受手术治疗的RCC合并肿瘤静脉血栓患者。中位年龄58岁(范围:16-82岁);男女比例为2.3:1。199例(25.9%)患者有静脉肿瘤血栓形成症状。在大多数患者中(n = 509;66.3%),肿瘤血栓起源于右肾静脉。肿瘤血栓的颅边界位于肾周下腔静脉(IVC) 219例(28.5%),肝下IVC 201例(26.2%),肝内IVC 171例(22.3%),膈上方177例(23.0%)。我们采用个体方法来选择最佳的血管控制方法,并确定循环支持的适应症。三分之二的患者(n = 512;66.7%)行暂时性肾第二静脉阻滞;268例(34.9%)-肝十二指肠韧带及右心暂时性阻滞;11例(3.2%)行体外循环手术。中位手术时间190±63.6 min;中位失血量为3000±71.6 mL(35.1%患者循环血液≥50%)。术中并发症23例(3.0%);术中死亡8例(1.0%),其中肺栓塞死亡4例(0.5%),失血性休克死亡3例(0.4%),心肌梗死死亡1例(0.1%)。190例(25.0%)出现术后并发症,其中Clavien-Dindo III-V级并发症115例(15.1%)。术后早期死亡41例(5.3%)。死亡原因包括多器官功能障碍(n = 21;2.8%),肺栓塞(n = 7;0.9%),败血症(n = 6;0.8%),中风(n = 4;0.5%)、心肌梗死(n = 2;0.2%)和RCC进展(n = 1;0.1%)。我们已经确定了几个院内死亡的独立危险因素,包括腹水(危险比(HR) 8.3;95%置信区间(CI) 3.2 ~ 21.4;p < 0.0001),术前肺栓塞(HR 3.5;95% ci 1.3-9.4;p = 0.013),膈上血栓(HR 1.5;95% ci 1.1-2.0;P = 0.003)。无危险因素的住院死亡率为3.5%(20/575),有1个危险因素的住院死亡率为9.8%(16/163),有2个危险因素的住院死亡率为40.0%(10/25),有3个危险因素的住院死亡率为60.0%(3/5)(曲线下面积(AUC) 0.705;p <0.0001)。肾癌合并肿瘤静脉血栓形成患者行肾切除术和取栓术的严重并发症发生率和术后死亡率分别为15.1%和6.4%。围手术期死亡的危险因素包括腹水、术前肺栓塞和膈上血栓形成。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Onkourologiya
Onkourologiya ONCOLOGY-
CiteScore
0.40
自引率
0.00%
发文量
59
审稿时长
10 weeks
期刊介绍: The main objective of the journal "Cancer urology" is publishing up-to-date information about scientific clinical researches, diagnostics, treatment of oncologic urological diseases. The aim of the edition is to inform the experts on oncologic urology about achievements in this area, to build understanding of the necessary integrated interdisciplinary approach in therapy, alongside with urologists, combining efforts of doctors of various specialties (cardiologists, pediatricians, chemotherapeutists et al.), to contribute to raising the effectiveness of oncologic patients’ treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信